Emergent BioSolutions Adds John Fowler to Board, Names Audit and Finance Committee Member
Emergent BioSolutions appointed John D. Fowler Jr. to its board effective March 1, 2026, and named him to the Audit and Finance Committee. Fowler brings over 30 years of leadership across healthcare and financial services, including senior roles at Wells Fargo Securities, Deutsche Bank and JPMorgan.
1. Emergent Names New Board Member
Emergent BioSolutions appointed John D. Fowler Jr. to its board of directors effective March 1, 2026, and confirmed his membership on the Audit and Finance Committee to bolster financial oversight.
2. Extensive Healthcare and Financial Experience
Fowler brings more than three decades of leadership in healthcare and financial services, having served as vice chairman at Wells Fargo Securities, vice chairman at Deutsche Bank, head of Health Care Services Banking at JPMorgan, and president of Large Scale Biology Corporation.
3. Role in Strategic Transformation
His deep expertise in financial markets and healthcare sectors is expected to support Emergent's ongoing turnaround efforts, strengthen governance, and drive execution of strategic priorities to enhance long-term shareholder value.